2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year. M&A & deals Synaffix continued to build momentum – Lonza acquired the […]
Fund to focus on its pioneering ‘asset-centric’ investment model, backing visionary biopharma entrepreneurs and drug hunters along the full drug development spectrum 27 July 2023, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces its $400 million Medicxi IV fund. The new fund will continue to support drug hunters with clear product […]
Significant support from investors including the European Investment Fund Fund to invest in first and best-in-class European life science companies in drug development and digital health Luxembourg-Strassen, 29 June 2023 – Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of […]
TargED is extremely pleased and proud to have raised €39 million in a Series A investment round! Together with an international investor syndicate we’ll pursue our common goal: to bring Microlyse into clinical development! Read press release
New Nordic fund focused on high-impact medical innovation Nine investments made over the first 16 months in early and late-stage healthcare companies. Two portfolio companies IPO’ed on NASDAQ New York December 9, 2021, Stockholm & Copenhagen: Eir Ventures Partners AB (“Eir Ventures” or “the Fund”), a Nordic Life Science Venture Capital manager, today announced the […]
